Distinguished in Warts

Dr. Fasahat Hamzavi

Dermatology
Hamzavi Pharmacy
2950 Keewahdin Rd, 
Fort Gratiot, MI 
Distinguished in Warts
Hamzavi Pharmacy
2950 Keewahdin Rd, 
Fort Gratiot, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Fasahat Hamzavi is a Dermatologist in Fort Gratiot, Michigan. Dr. Hamzavi is rated as a Distinguished provider by MediFind in the treatment of Warts. His top areas of expertise are Universal Acquired Melanosis, Liver Spots, Actinic Keratosis, and Warts.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Warts.

Specialties
Dermatology
Licenses
Dermatology in MI
Hospital Affiliations
Mclaren Port Huron
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Hamzavi Pharmacy
2950 Keewahdin Rd, Fort Gratiot, MI 48059

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Combination product
Study Phase: Phase 3
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
Enrollment Status: Completed
Publish Date: February 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

1 Total Publications

Neonatal dermatophytosis: report of a case and review of the literature.
Neonatal dermatophytosis: report of a case and review of the literature.
Journal: Pediatric dermatology
Published: April 21, 2011
Similar Doctors
Distinguished in Warts
Dr. Fred M. Novice
Dermatology
Distinguished in Warts
Dr. Fred M. Novice
Dermatology

Novice Aesthetis And Dermatology PLLC

4120 West Maple Road, Suite 206, 
Bloomfield Hills, MI 
 (17.2 miles away)
248-932-3376
Experience:
43+ years
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Fred Novice is a Dermatologist in Bloomfield Hills, Michigan. Dr. Novice has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Warts. His top areas of expertise are Epidermodysplasia Verruciformis, Epidermoid Cyst, Warts, and Eosinophilic Pustular Folliculitis. Dr. Novice is currently accepting new patients.

Julie A. Byrd
Distinguished in Warts
Dr. Julie A. Byrd
Dermatology
Distinguished in Warts
Dr. Julie A. Byrd
Dermatology

Rochester Dermatology Clinic PC

405 Barclay Circle, Suite 104, 
Rochester Hills, MI 
 (8.7 miles away)
248-853-3131
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Julie Byrd is a Dermatologist in Rochester Hills, Michigan. Dr. Byrd has been practicing medicine for over 26 years and is rated as a Distinguished provider by MediFind in the treatment of Warts. Her top areas of expertise are Neurocutaneous Melanosis, Actinic Keratosis, Giant Congenital Nevus, and Familial Atypical Multiple Mole Melanoma Syndrome. Dr. Byrd is currently accepting new patients.

Distinguished in Warts
Dr. George J. Murakawa
Dermatology
Distinguished in Warts
Dr. George J. Murakawa
Dermatology

Somerset Skin Centre

255 Kirts Boulevard, Suite 100, 
Troy, MI 
 (11.4 miles away)
248-244-8448
Experience:
34+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

George Murakawa is a Dermatologist in Troy, Michigan. Dr. Murakawa has been practicing medicine for over 34 years and is rated as a Distinguished provider by MediFind in the treatment of Warts. His top areas of expertise are Neurocutaneous Melanosis, Giant Congenital Melanocytic Nevus, Giant Congenital Nevus, and Familial Atypical Multiple Mole Melanoma Syndrome. Dr. Murakawa is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hamzavi's expertise for a condition
ConditionClose
    View All 32 Advanced Conditions
    View All 63 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile